Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Stephen Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R. Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E. Zijlstra; Malcolm E. Molyneux; John Dennis; Neil French

doi:10.1016/j.vaccine.2008.07.082

Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Stephen Gordon
, Rose Malamba
, Neema Mthunthama
, Elizabeth R. Jarman
, Kondwani Jambo
, Khuzwayo Jere
, Eduard E. Zijlstra
, Malcolm E. Molyneux
, John Dennis
, Neil French

Clinical Sciences

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	5400-5406
Number of pages	7
Journal	Vaccine
Volume	26
Issue number	42
DOIs	https://doi.org/10.1016/j.vaccine.2008.07.082
Publication status	Published - 3 Oct 2008

Keywords

Bronchoalveolar lavage
Immunoglobulin
Inhaled pneumococcal vaccine
Lung
Mucosa
Pneumonia
Polysaccharide
Streptococcus pneumoniae

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.07.082Licence: CC BY

SB Gordon Inhaled delivery of 23-valentOther version, 665 KBLicence: CC BY

Cite this

@article{e8c659ece512445488be9d7a8b4f95b4,

title = "Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses",

abstract = "We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.",

keywords = "Bronchoalveolar lavage, Immunoglobulin, Inhaled pneumococcal vaccine, Lung, Mucosa, Pneumonia, Polysaccharide, Streptococcus pneumoniae",

author = "Stephen Gordon and Rose Malamba and Neema Mthunthama and Jarman, \{Elizabeth R.\} and Kondwani Jambo and Khuzwayo Jere and Zijlstra, \{Eduard E.\} and Molyneux, \{Malcolm E.\} and John Dennis and Neil French",

year = "2008",

month = oct,

day = "3",

doi = "10.1016/j.vaccine.2008.07.082",

language = "English",

volume = "26",

pages = "5400--5406",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "42",

}

TY - JOUR

T1 - Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

AU - Gordon, Stephen

AU - Malamba, Rose

AU - Mthunthama, Neema

AU - Jarman, Elizabeth R.

AU - Jambo, Kondwani

AU - Jere, Khuzwayo

AU - Zijlstra, Eduard E.

AU - Molyneux, Malcolm E.

AU - Dennis, John

AU - French, Neil

PY - 2008/10/3

Y1 - 2008/10/3

N2 - We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.

AB - We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.

KW - Bronchoalveolar lavage

KW - Immunoglobulin

KW - Inhaled pneumococcal vaccine

KW - Lung

KW - Mucosa

KW - Pneumonia

KW - Polysaccharide

KW - Streptococcus pneumoniae

U2 - 10.1016/j.vaccine.2008.07.082

DO - 10.1016/j.vaccine.2008.07.082

M3 - Article

SN - 0264-410X

VL - 26

SP - 5400

EP - 5406

JO - Vaccine

JF - Vaccine

IS - 42

ER -

Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this